News
CEO Paul Bishop and President Lyle Camblos On Growth 2018 and Beyond
Each quarter, ARG CEO Paul Bishop and President Lyle Camblos will share their thoughts and responses concerning relevant company and […]
February 20, 2018
Flexible and Lightweight CRO Education: ARG Chrysalis Leads The Way
One of the main reasons why ARG has consistently produced excellent clinical trial work over the years has been because […]
January 28, 2018
ARG Has Big Plans For Rare Disease Day
Rare Disease Day is February 28th, and ARG is planning to participate in several ways. Locally, we are planning to […]
January 15, 2018
Prometic Announces FDA Acceptance of its BLA For Ryplazim
• Prescription Drug User Fee Act (PDUFA) action date is set for April 14, 2018• Ryplazim™ previously granted Fast Track, […]
October 13, 2017
Atlantic Research Group Forms Rare Disease Strategic Advisory Board to Accelerate Novel Medicines
Atlantic Research Group forms Rare Disease Strategic Advisory Board to accelerate novel medicines. Learn about this collaboration between patient advocacy […]
August 12, 2017
Why “CRA-centricity” Matters For Your Rare Disease Clinical Trial
Rare disease clinical trials also require extraordinary customer service—sometimes even including package delivery. In one case, each treatment dose cost […]
August 4, 2017